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Abstract
Astroglial type-1 cannabinoid (CB1) receptors are involved in synaptic transmission, plasticity and
behavior by interfering with the so-called tripartite synapse formed by pre- and post-synaptic neu-
ronal elements and surrounding astrocyte processes. However, little is known concerning the
subcellular distribution of astroglial CB1 receptors. In particular, brain CB1 receptors are mostly
localized at cells plasmalemma, but recent evidence indicates their functional presence in mito-
chondrial membranes. Whether CB1 receptors are present in astroglial mitochondria has remained
unknown. To investigate this issue, we included conditional knock-out mice lacking astroglial CB1
receptor expression specifically in glial fibrillary acidic protein (GFAP)-containing astrocytes (GFAP-
CB1-KO mice) and also generated genetic rescue mice to re-express CB1 receptors exclusively in
astrocytes (GFAP-CB1-RS). To better identify astroglial structures by immunoelectron microscopy,
global CB1 knock-out (CB1-KO) mice and wild-type (CB1-WT) littermates were intra-hippocampally
injected with an adeno-associated virus expressing humanized renilla green fluorescent protein
(hrGFP) under the control of human GFAP promoter to generate GFAPhrGFP-CB1-KO and -WT
mice, respectively. Furthermore, double immunogold (for CB1) and immunoperoxidase (for GFAP
or hrGFP) revealed that CB1 receptors are present in astroglial mitochondria from different hippo-
campal regions of CB1-WT, GFAP-CB1-RS and GFAPhrGFP-CB1-WT mice. Only non-specific gold
particles were detected in mouse hippocampi lacking CB1 receptors. Altogether, we demonstrated
the existence of a precise molecular architecture of the CB1 receptor in astrocytes that will have
to be taken into account in evaluating the functional activity of cannabinergic signaling at the tri-
partite synapse.
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1 | INTRODUCTION
Glial cells constitute the most abundant cell population in the central
nervous system. The astrocytes at the tripartite synapse establish bidir-
ectional communication with neurons by both intricate morphological
non-overlapping domains (Halassa, Fellin, Takano, Dong, & Haydon,
2007) and biochemical and signaling interactions (Araque et al., 2014;
Bezzi & Volterra, 2011) that play important roles in brain metabolic
processes (Magistretti & Allaman, 2015), in the maintenance and
regulation of synaptic physiology (Araque et al., 2014; Perez-Alvarez,
Navarrete, Covelo, Martin, & Araque, 2014) and in brain information
processing (Volterra & Meldolesi, 2005).
The endocannabinoid (eCB) system is composed of the seven-
transmembrane G protein coupled cannabinoid type-1 (CB1) receptor
and other receptors (including CB2 receptors), their endogenous lipid
ligands (endocannabinoids) and the proteins involved in synthesis,
transport and degradation of the endocannabinoids (Katona & Freund,
2012; Lutz, Marsicano, Maldonado, & Hillard, 2015; Pertwee, 2015;
Piomelli, 2003). This system is widely distributed in the central and
peripheral nervous system (Katona & Freund, 2012; Lu & Mackie,
2016), and also in peripheral organs (Piazza, Cota, & Marsicano, 2017),
where the CB1 receptors are also localized in mitochondria of striated
and heart muscles (Mendizabal-Zubiaga et al., 2016). The eCB system
regulates brain functions by acting on different cell types and cellular
compartments (Busquets-Garcia, Bains, & Marsicano, 2018; Gutierrez-
Rodríguez et al., 2017; Katona & Freund, 2012; Lu & Mackie, 2016).
The activation of CB1 receptors in astrocytes promotes astroglial differ-
entiation (Aguado et al., 2006) and mediates neuron-astrocyte commu-
nication that plays a role in synaptic plasticity, memory and behavior
(Araque et al., 2014; Gomez-Gonzalo et al., 2015; Han et al., 2012;
Metna-Laurent & Marsicano, 2015; Navarrete & Araque, 2008, 2010;
Navarrete, Diez, & Araque, 2014; Oliveira da Cruz, Robin, Drago,
Marsicano, & Metna-Laurent, 2015). Furthermore, CB1 receptor activa-
tion is involved in energy supply to the brain through the control of
leptin receptor expression in astrocytes (Bosier et al., 2013).
The CB1 receptor-mediated astrocyte functions are highly depend-
ent on the CB1 receptor distribution in astrocytes relative to close neu-
ronal compartments, particularly at synapses (Bonilla-Del Río et al.,
2017). However, the low CB1 receptor expression in astrocytes (Bosier
et al., 2013; Han et al., 2012; Kovacs et al., 2017; Rodriguez, Mackie, &
Pickel, 2001) and mitochondria (Benard et al., 2012; Hebert-Chatelain
et al., 2014a; b; 2016) constrains a consolidated picture of the subcellu-
lar CB1 receptor distribution in the astroglial compartments that holds
the anatomical substrate for a functional interaction with the nearby
synapses under normal or pathological conditions (Bonilla-Del Río et al.,
2017). Yet, whether intracellular CB1 receptors exist in astroglial mito-
chondria has remained unknown. In the hippocampus, mitochondrial
CB1 (mtCB1) receptor activation affects synaptic transmission and
memory formation through reduced phosphorylation of specific subu-
nits of the complex I electron transport system, and through decreased
mitochondrial respiration and mobility (Hebert-Chatelain et al., 2016).
These effects are due to intra-mitochondrial Gai protein activation by
mtCB1 receptors that leads to the inhibition of soluble adenylyl cyclase
and, consequently, to the decrease in intra-mitochondrial protein kinase
A (PKA) activity (Hebert-Chatelain et al., 2016). New tools based on
genetic rescue strategies have proven to be useful to dissect the suffi-
ciency of the CB1 receptors expressed in specific cell types for a partic-
ular brain function (de Salas-Quiroga et al., 2015; Gutierrez-Rodríguez
et al., 2017; Lange et al., 2017; Remmers et al., 2017; Ruehle et al.,
2013; Soria-Gomez et al., 2014). Importantly, knock-in mice with cell
type-specific rescue of CB1 receptors in dorsal telencephalic glutama-
tergic neurons (Glu-CB1-RS) or GABAergic neurons (GABA-CB1-RS)
showed that the distribution pattern and the subcellular CB1 receptor
localization is maintained as it is observed in the wild-type hippocampus
(Gutierrez-Rodríguez et al., 2017; Remmers et al., 2017).
In this study, we hypothesized that intracellular CB1 receptors are
present in astroglial mitochondria as observed in neuronal and muscular
mitochondria. The GFAP-CB1-RS rescue mice expressing the CB1
receptor gene exclusively in the astrocytes and the GFAPhrGFP-CB1-
WT mice are ideal genetic tools to test this hypothesis. Our results
show that the subcellular CB1 receptor distribution in astrocytes in the
rescue mice completely matches the endogenous CB1 receptor expres-
sion and localization in astrocytes of the wild-type mouse hippocam-
pus. Moreover, our findings illustrate for the first time the localization
of CB1 receptors in astroglial mitochondria.
2 | MATERIALS AND METHODS
2.1 | Animal procedures
2.1.1 | Ethics statement
Experiments were approved by the Committee of Ethics for Animal
Welfare of the University of the Basque Country UPV/EHU (CEIAB/
2016/074, CEEA/M20/2016/073) and the Committee on Animal
Health and Care of INSERM and the French Ministry of Agriculture
and Forestry (authorization number, A501350). All animals were used
according to the European Community Council Directive 2010/63/UE
and the Spanish and French legislation (RD 53/2013 and Ley 6/2013).
Maximal efforts were made in order to minimize the number and the
suffering of the animals used.
2.1.2 | Conventional and conditional CB1-KO
CB1-KO mice were generated and genotyped as previously described
(Marsicano et al., 2002). In addition, conditional CB1 receptor mutant
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mice were obtained by crossing the respective Cre expressing mouse
line with CB1
f/f mice (Marsicano et al., 2003), using a three-step breed-
ing protocol (Monory et al., 2006). Specifically, transgenic mice express-
ing the inducible version of the Cre recombinase CreERT2 under the
control of the human glial fibrillary acid protein promoter, i.e. GFAP-
CreERT2 mice (Hirrlinger, Scheller, Braun, Hirrlinger, & Kirchhoff, 2006)
were crossed with mice carrying CB1 receptor “floxed” sequence (Mar-
sicano et al., 2003). As a result, transgenic mice CB1
f/f;GFAP-CreERT2 were
obtained (Han et al., 2012).
2.1.3 | Generation of GFAP-CB1-RS
STOP-CB1 mice were previously generated by inserting a loxP-flanked
stop cassette into the 50UTR of the coding exon of the CB1 gene, 32
nucleotides upstream of the translational start codon (Ruehle et al.,
2013). The STOP-CB1 mice were crossed with GFAP-CreERT2 mice
(Hirrlinger, Scheller, Braun, Hirrlinger, & Kirchhoff, 2006) to obtain
CB1
stop/stop;GFAP-CreERT2 mice.
Seven to nine-week-old CB1
f/f;GFAP-CreERT2 and CB1
f/f littermates,
as well as CB1
stop/stop;GFAP-CreERT2 and CB1
stop/stop littermates were
treated daily for eight consecutive days with 1 mg/kg (i.p.) of either
tamoxifen or 4OH-tamoxifen synthesized as previously reported (Detsi,
Koufaki, & Calogeropoulou, 2002; Yu & Forman, 2003) to induce the
Cre-dependent astroglial deletion of CB1 (GFAP-CB1-KO and GFAP-
CB1-WT littermate mice) or its exclusive astroglial re-expression (res-
cue, GFAP-CB1-RS and STOP-CB1 littermates). Mice were used for
immunocytochemistry 3–5 weeks after the last day of tamoxifen or
4OH-tamoxifen injections.
2.1.4 | Generation of GFAPhrGFP-CB1-WT and
GFAPhrGFP-CB1-KO mice
Intrahippocampal injection of a recombinant adeno associated virus
expressing hrGFP under the control of the human GFAP promoter (von
Jonquieres et al., 2013) were performed in CB1-WT and CB1-KO mice
to generate GFAPhrGFP-CB1-WT and GFAPhrGFP-CB1-KO, respec-
tively. The vector backbone was the pAAV-GFAP-hChR2(H134R)-
EYFP kindly provided by Karl Deisseroth (Stanford University, CA,
USA). We replaced the hChR2(H134R)-EYFP with the cDNA encoding
for hrGFP by using standard molecular cloning techniques. The virus
production and purification, as well as the injection procedure were
performed as previously described (Chiarlone et al., 2014). Coordinates
for intrahippocampal injections were: anteroposterior – 2.0 mm, medio-
lateral 6 1.5 mm, dorsoventral – 2 mm relative to bregma. Mice were
allowed to recover for at least 4 weeks after surgery before their ana-
tomical characterization.
2.1.5 | Tissue isolation
Mice were housed under standard conditions (ad libitum food and
water; 12hr/12hr light/dark cycle). CB1-WT, GFAP-CB1-RS, GFAP-CB1-
KO, CB1-KO, STOP-CB1, GFAPhrGFP-CB1-WT and GFAPhrGFP-CB1-
KO mice (3 animals of each condition) were deeply anesthetized by
intraperitoneal injection of ketamine/xylazine (80/10 mg/kg body
weight) and transcardially perfused at room temperature (RT, 208C–
258C) with phosphate buffered saline (.1 M PBS, pH 7.4) for 20 s,
followed by the fixative solution (4% formaldehyde freshly depolymer-
ized from paraformaldehyde, .2% picric acid and .1% glutaraldehyde) in
PBS (.1 M, pH 7.4) for 10–15 min. Brains were removed from the skull
and post-fixed in the fixative solution for about 1 week at 48C and
stored at 48C in 1:10 diluted fixative solution until use.
2.1.6 | Double pre-embedding immunogold and
immunoperoxidase method for electron microscopy
Coronal hippocampal vibrosections were cut at 50 mm and collected in
phosphate buffer (.1 M PB, pH 7.4) with .1% sodium azide at RT. They
were transferred and pre-incubated in a blocking solution of 10%
bovine serum albumin (BSA), .1% sodium azide and .02% saponine pre-
pared in Tris-hydrogen chloride buffered saline 13 (TBS), pH 7.4 for
30 min at RT. Then, the CB1-WT, GFAP-CB1-RS, GFAP-CB1-KO, CB1-
KO and STOP-CB1 tissue sections were incubated with the primary
goat polyclonal anti-CB1 receptor antibody (2 mg/ml, #CB1-Go-Af450,
Frontier Institute Co. Ltd, Ishikari, Hokkaido, Japan, RRID: AB_257130)
and mouse monoclonal anti-GFAP antibody (1:1,000, #G3893, Sigma-
Aldrich, St. Louis, MO, USA, RRID: AB_477010) diluted in 10% BSA/
TBS containing .1% sodium azide and .004% saponine on a shaker for 2
days at 48C. In parallel, GFAPhrGFP-CB1-WT and GFAPhrGFP-CB1-KO
hippocampi were incubated with the same primary goat polyclonal
anti-CB1 receptor antibody as above and rabbit polyclonal anti-
hrGFP antibody (1:500, #240142-51, Stratagene-Agilent, Santa Clara,
CA, USA, RRID: AB_10598674) in 10% BSA/TBS with .1% sodium
azide and .004% saponine for 2 days at 48C.
The tissue was incubated after several washes in 1% BSA/TBS
with the corresponding biotinylated secondary antibody (1:200 biotin-
ylated anti-mouse, BA-2000; RRID:AB_2313581, and 1:200 biotinyl-
ated anti-rabbit BA-1000; RRID:AB_2313606, Vector Labs,
Burlingame, CA, USA) in 1% BSA/TBS with .004% saponine for 3 hr at
RT. The sections were washed in 1% BSA/TBS overnight on a shaker
at 48C, incubated with the secondary 1.4 nm gold-labeled immunoglob-
ulin-G antibody (Fab’ fragment, 1:100, Nanoprobes Inc., Yaphank, NY,
USA) in 1% BSA/TBS with .004% saponine on a shaker for 3 hr at RT,
washed in 1% BSA/TBS and subsequently incubated in the avidin-
biotin complex (1:50; PK-7100, Vector Labs, Burlingame, CA, USA)
diluted in the wash solution for 1.5 hr. After washing the sections in
1% BSA/TBS overnight at 48C, they were post-fixed with 1% glutaral-
dehyde in TBS for 10 min and washed in double-distilled water. Then,
the gold particles were silver-intensified with a HQ Silver kit (Nanop-
robes Inc., Yaphank, NY, USA) for about 12 min in the dark, washed in
.1 M PB (pH 7.4) and subsequently incubated in .05% diaminobenzidine
(DAB) and .01% hydrogen peroxide prepared in .1 M PB for 3 min.
Finally, the sections were osmicated (1% osmium tetroxide, in .1 M PB
pH 7.4) for 20 min, washed in .1 M PB (pH 7.4), dehydrated in graded
alcohols (50%–100%) to propylene oxide and plastic-embedded in
Epon resin 812. 50-60 nm-ultrathin sections were cut with a diamond
knife (Diatome USA), collected on nickel mesh grids or on formvar-
coated single slot grids for serial sectioning, stained with 2.5% lead
citrate, and examined with a Philips EM208S electron microscope. Tis-
sue preparations were photographed by means of a digital camera
coupled to the electron microscope. Minor adjustments in contrast and
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brightness were made to the figures using Adobe Photoshop (Adobe
Systems, San Jose, CA, USA). GIMP (GNU Project) and Adobe Photo-
shop were used to blend the electron micrographs into the serial
photocomposition.
2.1.7 | Semi-quantification of the CB1 receptor immunogold
and immunoperoxidase staining
The pre-embedding immunogold and immunoperoxidase methods
were simultaneously applied and repeated three times on the sections
obtained from each of the three individual CB1-WT, GFAP-CB1-RS,
GFAP-CB1-KO, CB1-KO, STOP-CB1, GFAPhrGFP-CB1-WT and
GFAPhrGFP-CB1-KO animals studied. Immunogold-labeling was visual-
ized on the hippocampal sections with a light microscope and portions
of the CA1 stratum radiatum and the dentate molecular layer with
good and consistent CB1 receptor immunolabeling were identified and
trimmed down for ultrathin sectioning. Three to four semi-thin sections
(1 mm-thick) were then cut with a histo-diamond knife (Diatome USA)
and stained with 1% toluidine blue. To further standardize the condi-
tions, only the first 20 ultrathin sections (60 nm thick) were cut, col-
lected onto the grids and photographed. The electron micrographs
were taken at 18,0003 with a Digital Morada Camera from Olympus
(Hamburg, Germany). Sampling was always carefully and accurately car-
ried out in the same way for all the animals studied and it was blinded
to experimenters during CB1 receptor quantification.
Positive astrocytic processes were identified by the presence of
DAB immunodeposits. Positive CB1 receptor labeling was considered if
at least one immunoparticle was within 30 nm of the plasmalemma
or outer mitochondrial membranes. Furthermore, only particles on
mitochondrial membrane segments far away from other astrocytic
membranes (distance 80 nm) and well distinct from the astrocytic
intermediate filaments or any other intracellular organelle membranes
were taken into account for mitochondrial localization. Image-J soft-
ware (NIH; RRID:SCR_003070) was used to measure the membrane
length. Percentages of CB1 receptor positive profiles (astrocytic proc-
esses and mitochondria), density (particles/mm membrane), the propor-
tion of CB1 receptor particles in astrocytes versus total CB1 receptor
expression and the proportion of CB1 receptor particles in terminals
versus total CB1 receptor expression in plasmalemma, were analyzed
and displayed as mean6 SEM using a statistical software package
(GraphPad Prism 5, GraphPad Software Inc, San Diego, USA; RRID:
SCR_002798). The normality test (Kolmogorov-Smirnov normality test)
was applied before statistical tests and subsequently data were ana-
lyzed using nonparametric tests (Mann-Whitney U test when k52 or
Kruskal-Wallis test when k>2). Potential variability between animals of
the same mutant mouse line was assessed statistically. Because no dif-
ferences were detected, all data within each mouse line were pooled.
2.1.8 | Semi-quantification of the distance from the CB1
receptor particles in astroglial mitochondria to the nearest
synapse
Image-J software was used to measure the distance between the CB1
receptor immunogold particles on the astrocytic mitochondria and the
nearest synapse on single 60 nm-thick sections. Data were tabulated,
analyzed and displayed as mean6 SEM using GraphPad Prism 5
software.
3 | RESULTS
3.1 | Subcellular CB1 receptor localization in the
mutant mice
Astrocytes and their processes were identified by DAB immunodepo-
sits of GFAP or hrGFP and the CB1 receptor was detected by immuno-
gold labeling. As expected, the CB1 receptor was mainly localized on
neuronal terminals, preterminal membranes and, to a lesser extent, on
GFAP-labeled astrocytes. CB1 receptor-immunopositive synaptic termi-
nals followed in serial ultrathin sections obtained from the CA1 (Figure
1) and dentate molecular layer (Figure 2) of the CB1-WT mouse could
be found adjacent to double-labeled GFAP and CB1 receptor-
immunopositive astrocytic processes (Figures 1–3a and 4a) that also
contained CB1 receptor-immunopositive mitochondria (Figures 1–4). In
GFAP-CB1-RS hippocampus, the CB1 receptor immunolabeling was
restricted to the DAB-containing astrocytic elements and no labeling
was found on axon boutons (Figures 3c and 4c). Conversely, the CB1
receptor particles in the GFAP-CB1-KO hippocampus were only on syn-
aptic terminals but not in astrocytic processes (Figures 3d and 4d).
Also, CB1 receptor immunoparticles were found in neuronal mitochon-
dria but not in mitochondria of astrocytes in the GFAP-CB1-KO (Figure
3d). Finally, the subcellular distribution of the CB1 receptor on synaptic
terminals and astrocytic elements of the GFAPhrGFP-CB1-WT
resembled the CB1-WT hippocampus (Figures 3f,g and 4f,g). Impor-
tantly, this CB1 receptor staining pattern was absent in CB1-KO
(Figures 3b and 4b), STOP-CB1 (Figures 3e and 4e) and GFAPhrGFP-
CB1-KO mice (Figures 3h and 4h).
3.2 | CB1 receptor assessment in astrocytes of the
CA1 stratum radiatum
The percentage of the CB1 receptor immunopositive astrocytic proc-
esses in the CA1 stratum radiatum of the GFAP-CB1-RS (37.12%6
3.79%) was not statistically different (p> .05; Figure 5a) relative to the
CB1-WT mouse (42.06%63.56%), however the proportion in the
GFAPhrGFP-CB1-WT was significantly higher (59.91%63.29%;
***p< .001; Figure 5a). Only background metal particles were found in
CA1 astrocytes of the STOP-CB1, GFAP-CB1-KO, CB1-KO and
GFAPhrGFP-CB1-KO mice (***p< .001; Figure 5a).
The density of CB1 receptor immunoparticles on astrocytic mem-
branes (particles/mm) was also analyzed (Figure 5b). Similar densities
were detected in the GFAP-CB1-RS (.1286 .020) and the CB1-WT
(.1356 .019; p> .05; Figure 5b) however the density was much higher
in the GFAPhrGFP-CB1-WT (.3846 .039; ***p< .001; Figure 5b). Only
residual non-specific particles were observed in the STOP-CB1 (.0056
.003), GFAP-CB1-KO (.0056 .003), CB1-KO (.0016 .001) and
GFAPhrGFP-CB1-KO mice (.0046 .002; ***p< .001; Figure 5b).
5.31%6 .84% of the total CB1 receptor labeling in the CB1-WT,
11.97%62.17% in the GFAPhrGFP-CB1-WT (p> .05; Figure 5c) and
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95.31%61.87% in the GFAP-CB1-RS were in astrocytic processes
(***p< .001; Figure 5c). Only background immunoparticles were
detected in astrocytic processes of the STOP-CB1, GFAP-CB1-KO, CB1-
KO and GFAPhrGFP-CB1-KO (***p< .001; Figure 5c). As a comparison,
65.52%62.44% of the total CB1 receptor gold particles in the CB1-
WT, 75.13%64.06% in the GFAP-CB1-KO and 56.32%62.73% in the
GFAPhrGFP-CB1-WT were distributed on synaptic terminals (p> .05;
Figure 5d). Scattered metal particles were found in GFAP-CB1-RS,
STOP-CB1, CB1-KO and GFAPhrGFP-CB1-KO mice (***p< .001;
Figure 5d).
3.3 | CB1 receptor assessment in astrocytes of the
dentate molecular layer
The proportion of the CB1 receptor immunopositive astrocytic proc-
esses in the GFAP-CB1-RS (39.84%63.50%) and the CB1-WT
(44.67%63.85%) was statistically similar (p> .05; Figure 6a), but it
was significantly higher in the GFAPhrGFP-CB1-WT group (59.99%6
3.37%; **p< .01; Figure 6a). Particles were virtually undetectable in
the STOP-CB1, GFAP-CB1-KO, CB1-KO and GFAPhrGFP-CB1-KO mice
(***p< .001; Figure 6a).
The CB1 receptor density (particles/mm) on astrocytic membranes
did not differ statistically between the GFAP-CB1-RS (.1386 .016) and
the CB1-WT (.1126 .011; p> .05; Figure 6b) but it was higher in the
GFAPhrGFP-CB1-WT group (.3346 .033; ***p< .001; Figure 6b). Neg-
ligible particle numbers were noticed in the STOP-CB1 (.0066 .003),
GFAP-CB1-KO (.0066 .003), CB1-KO (.0046 .002) and GFAPhrGFP-
CB1-KO (.0026 .002; ***p< .001; Figure 6b).
Of the total CB1 receptor labeling, 5.35%61.00% in the CB1-WT,
13.13%62.60% in the GFAPhrGFP-CB1-WT (P> .05; Figure 6c) and
95.61%61.56% in the GFAP-CB1-RS was in astrocytes (***P< .001;
Figure 6c). Non-specific CB1 receptor immunoparticles were found on
FIGURE 1 Follow up of a CB1 receptor positive astrocytic process in the CA1 stratum radiatum of CB1-WT. Double pre-embedding immu-
nogold (CB1 receptor) and immunoperoxidase (GFAP) method for electron microscopy. Serial ultrathin sections showing a GFAP positive
(DAB immunodeposits) astrocytic process (as) with a few CB1 receptor immunoparticles on the astrocytic membrane throughout the recon-
struction (b–f). In the astrocyte, CB1 receptor labeling is also observed on the mitochondrial membrane (d). A CB1 receptor-positive terminal
(ter) is closely associated to the astrocytic process. Black thin arrows: neuronal CB1 receptor labeling; black thick arrows: astrocytic CB1
receptor labeling; white arrow: mitochondrial CB1 receptor labeling in astrocyte; as: astrocytic process; ter: axon terminal; m: CB1 receptor-
positive mitochondria in astrocyte. Scale bar: 0.5 mm
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astrocytic processes in the STOP-CB1, GFAP-CB1-KO, CB1-KO and
GFAPhrGFP-CB1-KO mice (***P< .001; Figure 6c). Conversely,
64.27%62.88% of the total CB1 receptor labeling in the CB1-WT,
76.17%64.70% in the GFAP-CB1-KO and 57.17%62.19% in the
GFAPhrGFP-CB1-WT was located on synaptic terminals (P> .05; Fig-
ure 6d). Residual metal particles were detected in the GFAP-CB1-RS,
STOP-CB1, CB1-KO and GFAPhrGFP-CB1-KO (***P< .001; Figure 6d).
3.4 | CB1 receptor localization in astroglial
mitochondria
CB1 receptor labeling was observed in mitochondria (mtCB1 receptors)
of astrocytes distributed throughout the CA1 stratum radiatum (Figures
1d and 3a,c,g) and dentate molecular layer (Figures 2a,f and 4a,c,f,g). In
CB1-WT mice, 11.12%61.80% of the astrocytic mitochondrial sec-
tions in the CA1 stratum radiatum and 11.56%62.33% in the dentate
molecular layer were CB1 receptor immunopositive (Figures 7a,b). The
percentage was roughly similar in GFAP-CB1-RS (CA1 stratum radia-
tum: 12.39%61.81% (p> .05; Figure 7a); dentate molecular layer:
11.48%61.76% (p> .05; Figure 7b) and GFAPhrGFP-CB1-WT (CA1
stratum radiatum: 13.12%62.53% (P> .05; Figure 7a); dentate
molecular layer: 13.74%63.20% (p> .05; Figure 7b). Non-specific
mitochondrial particles were detected in STOP-CB1 (CA1 stratum radia-
tum: 4.66%61.55%, **p< .01; Figure 7a; dentate molecular layer:
5.38%61.22%, *p< .05; Figure 7b), GFAP-CB1-KO (CA1 stratum radi-
atum: 3.97%61.70%, **p< .01; Figure 7a; dentate molecular layer:
3.04%61.04%, **p< .01; Figure 7b), CB1-KO (CA1 stratum radiatum:
2.97%61.15%. ***p< .001; Figure 7a; dentate molecular layer:
2.49%6 .80%, ***p< .001; Figure 7b) and GFAPhrGFP-CB1-KO mice
(CA1 stratum radiatum: .95%6 .95%, ***p< .001; Figure 7a; dentate
molecular layer: 1.98%6 .91%, ***p< .001; Figure 7b).
3.5 | Distance from the astroglial mtCB1 receptors to
the nearest synapse
The distance between the astrocytic mtCB1 receptor particles and the
midpoint of the nearest synapse was assessed in CB1-WT, GFAP-CB1-
RS and GFAPhrGFP-CB1-WT hippocampi (Figure 8; table 1). In the
CA1, 10.55%64.01% of the total synapses analyzed were in a range
of 0–400 nm from the astrocytic mtCB1 receptor particles in CB1-WT,
2.67%62.67% in GFAP-CB1-RS and 7.41%63.70% in GFAPhrGFP-
CB1-WT. 38.54%68.32% of the synapses were located between 400
FIGURE 2 Follow up of a CB1 receptor-positive astrocytic process in the dentate molecular layer of CB1-WT. Double pre-embedding
immunogold (CB1 receptor) and immunoperoxidase (GFAP) method for electron microscopy. Serial ultrathin sections showing a GFAP posi-
tive (DAB immunodeposits) astrocytic process (as) with scattered CB1 receptor immunoparticles on the astrocytic (a,c,f) and mitochondrial
(a,f) membranes. A CB1 receptor-positive synaptic terminal (ter) is related to the astrocytic process. Black thin arrows: neuronal CB1
receptor labeling; black thick arrows: astrocytic CB1 receptor labeling; white arrows: mitochondrial CB1 receptor labeling in astrocyte; as:
astrocytic process; ter: axon terminal; m: CB1 receptor-positive mitochondria in astrocyte. Scale bar: 1 mm
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and 800 nm in CB1-WT, 49.28%62.87% in GFAP-CB1-RS and
51.85%63.70% in GFAPhrGFP-CB1-WT. 29.51%66.85% of the
synapses were detected between 800 and 1,200 nm in CB1-
WT, 37.26%62.02% in GFAP-CB1-RS and 29.63%67.41% in
GFAPhrGFP-CB1-WT. Finally, 21.40%65.56% of the synapses were
found at more than 1,200 nm from the astrocytic mtCB1 receptor in
CB1-WT, 10.79%62.94% in GFAP-CB1-RS and 14.81%67.41% in
GFAPhrGFP-CB1-WT (Figure 8; Table 1). In the dentate molecular
layer, 11.11%66.42% of the total synapses analyzed were at 0–
400 nm in CB1-WT, 2.82%61.48% in GFAP-CB1-RS and 1.52%6
1.52% in GFAPhrGFP-CB1-WT. 50%63.21% of the synapses were
located at a distance of between 400 and 800 nm from the astrocytic
mtCB1 immunoparticle in CB1-WT, 47.57%64.81% in GFAP-CB1-RS
and 57.37%66.26% in GFAPhrGFP-CB1-WT. 23.15%6 .93% of them
were located between 800 and 1,200 nm in CB1-WT, 43.79%63.13%
in GFAP-CB1-RS and 35.86%62.53% in GFAPhrGFP-CB1-WT. Finally,
18.52%63.70% of the synapses in CB1-WT, 11.82%63.51% in
GFAP-CB1-RS and 5.25%62.72% in GFAPhrGFP-CB1-WT were
observed at more than 1,200 nm from the astrocytic mtCB1 receptor
particles (Figure 8; Table 1).
FIGURE 3 CB1 receptor localization in identified astrocytes and astrocytic mitochondria in the CA1 stratum radiatum of mutant mice. Pre-
embedding immunogold and immunoperoxidase method for electron microscopy. In CB1-WT (a), CB1 receptor immunoparticles are localized
on membranes of astrocytic processes. Mitochondrial CB1 receptor labeling is also visualized in identified astrocytes of CB1-WT (a). As
expected, CB1 receptor immunoparticles are also on membranes of synaptic terminals and preterminals (a). No CB1 receptor immunolabeling
is detected in CB1-KO (b), confirming the specificity of the CB1 receptor antibody. Astrocytic processes, but not axon terminals, are CB1
receptor immunopositive in GFAP-CB1-RS (c). Note in this mutant, CB1 receptor labeling on the outer membrane of an astrocytic mito-
chondrion (c). CB1 receptor particles are found in synaptic terminals and neuronal mitochondria, but not in astrocytes and astrocytic mito-
chondria, of GFAP-CB1-KO (d). No CB1 receptor immunoparticles are observed in STOP-CB1 (e). In GFAPhrGFP-CB1-WT (f and g),
presynaptic terminals and astrocytic processes are CB1 receptor positive. Mitochondrial CB1 receptor labeling is also visualized in identified
astrocytes (g). No CB1 receptor immunolabeling is detected in GFAPhrGFP-CB1-KO (h). Black arrowheads: excitatory synapses; white arrow-
heads: inhibitory synapses; black thin arrows: neuronal CB1 receptor immunoparticles; black thick arrows: astrocytic CB1 receptor immuno-
particles; white thick arrows: mitochondrial CB1 receptor labeling in astrocytes; white thin arrows: mitochondrial CB1 receptor labeling in
neurons; as: astrocytic processes; ter: terminal; den: dendrite; sp: dendritic spine; m: CB1 receptor-positive astroglial/neuronal mitochondria.
Scale bars: 0.5 mm
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4 | DISCUSSION
The high CB1 receptor expression in the hippocampus is unevenly dis-
tributed between subcellular compartments of GABAergic and gluta-
matergic synaptic terminals, astrocytes and neuronal mitochondria
(Benard et al., 2012; Gutierrez-Rodríguez et al., 2017; Han et al., 2012;
Hebert-Chatelain et al., 2014a,b, 2016; Katona & Freund, 2012; Lu &
Mackie, 2016; Marsicano & Lutz, 1999; Steindel et al., 2013). However,
no information is available to date whether the CB1 receptor localizes
in astroglial mitochondria as it does in mitochondria of hippocampal
GABAergic and glutamatergic neurons (Benard et al., 2012; Hebert-
Chatelain et al., 2014a,b, 2016). In order to address this, we used con-
ditional CB1 receptor rescue mice re-expressing the CB1 receptor
exclusively in astrocytic GFAP expressing cells (GFAP-CB1-RS), as well
as CB1-WT and CB1-KO mice expressing hrGFP (De Francesco et al.,
2015; Hadaczek et al., 2009; Kerr et al., 2015; Navarro-Galve et al.,
2005; Ward & Cormier, 1979) under the control of the GFAP promoter
(GFAPhrGFP-CB1-WT and GFAPhrGFP-CB1-KO, respectively). As a
FIGURE 4 CB1 receptor localization in identified astrocytes and astrocytic mitochondria in the dentate molecular layer of mutant mice.
Pre-embedding immunogold and immunoperoxidase method for electron microscopy. In CB1-WT, CB1 receptor immunoparticles are local-
ized on membranes of presynaptic terminals, astrocytic processes as well as on mitochondrial membranes of identified astrocytes (a). Impor-
tantly, the CB1 receptor labeling is absent in CB1-KO (b). In GFAP-CB1-RS, CB1 receptor gold particles are only detected on astrocytes and
astrocytic mitochondria but not on neuronal synaptic compartments (c). Conversely, CB1 receptor immunolabeling is only present on synap-
tic boutons and not on astrocytes of GFAP-CB1-KO (d). The CB1 receptor labeling is not observed in the STOP-CB1 mouse (e). In
GFAPhrGFP-CB1-WT, CB1 receptor immunoparticles are localized on membranes of presynaptic terminals, astrocytic processes and astro-
cytic mitochondria (f and g). No CB1 receptor immunolabeling is detected in GFAPhrGFP-CB1-KO (h). Black arrowheads: excitatory synapses;
white arrowheads: inhibitory synapses; black thin arrows: neuronal CB1 receptor immunoparticles; black thick arrows: astrocytic CB1 recep-
tor immunoparticles; white arrows: mitochondrial CB1 receptor labeling in astrocytes; as: astrocytic processes; ter: terminal; den: dendrite;
sp: dendritic spine; m: CB1 receptor-positive astrocytic mitochondria. Scale bars: 0.5 mm
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first step, we determined the CB1 receptor expression and distribution
in the conditional mutant mice in order to draw the level of agreement
with the CB1 receptor expression pattern in the CB1-WT mice. The
combined pre-embedding immunogold and immunoperoxidase method
applied in this study has been previously proven to be an excellent
approach for the localization of the CB1 receptor in astrocytes (Bonilla-
Del Río et al., 2017; Bosier et al., 2013; Han et al., 2012) and mitochon-
dria (Benard et al., 2012; Hebert-Chatelain et al., 2014a,b, 2016). Speci-
ficity control experiments of the CB1 receptor antibodies were carried
out in CB1-KO and STOP-CB1 mice (carrying a loxP-flanked stop cas-
sette inserted into the sequences of the 5’UTR of the CB1 receptor).
According to recent observations, we detected very low levels of metal
particle deposits in STOP-CB1 (Remmers et al., 2017) and scattered
background particles in CB1-KO.
The results showed that the proportion and density of the CB1
receptor immunolabeling (particles/lm) of astrocytic processes in the
hippocampus were not significantly different between GFAP-CB1-RS
and CB1-WT. The percentage of immunopositive astrocytes in CA1 of
CB1-WT was in the range of the previous values reported by our group
(Bonilla-Del Río et al., 2017; Han et al., 2012), and almost all of the CB1
receptor labeling was expressed in astrocytic elements in GFAP-CB1-
RS. Furthermore, the proportion of astrocytic processes expressing
CB1 receptors and the density of receptor particles were about 34%
and 64% higher, respectively, in the mutant mice targeted to express
hrGFP in astroglial cells (GFAPhrGFP-CB1-WT) than in GFAP-CB1-RS.
These results suggest that the CB1 receptor expression in astrocytes
could actually be higher than previously reported using the astrocytic
GFAP marker (Bosier et al., 2013; Han et al., 2012), because the GFAP
FIGURE 5 Statistical assessment of the CB1 receptor distribution on astrocytes in the CA1 stratum radiatum of the mutant mice. (a).
Percentages of CB1 receptor immunopositive astrocytic processes in CB1-WT (42.06%63.56%) and GFAP-CB1-RS (37.12%63.79%) do not
show statistical differences. The proportion of 59.91%63.29% in GFAPhrGFP-CB1-WT is statistically significant. Only residual background
is found in STOP-CB1 (1.46%6 .78%), GFAP-CB1-KO (1.45%6 .77%), CB1-KO (.54%6 .39%) and GFAPhrGFP-CB1-KO (1.16%6 .67%). The
number of astrocytic processes examined is in parentheses on the top of each column. (b). CB1 receptor immunoparticle density on
membranes of astrocytic processes (particles/mm). Densities in CB1-WT (.1356 .019) and GFAP-CB1-RS (.1286 .020) are statistically similar,
whereas a significant increase in particle density is found in GFAPhrGFP-CB1-WT (.3846 .039). Non-specific particles are detected in
STOP-CB1 (.0056 .003), GFAP-CB1-KO (.0056 .003), CB1-KO (.0016 .001) and GFAPhrGFP-CB1-KO (.0046 .002). (c) Proportion of CB1
receptor gold particles on astrocytic membranes versus total CB1 receptor expression on plasmalemma: 5.31%6 .84% of the total CB1
receptor immunoparticles are located in astrocytes of CB1-WT and 95.31%61.87% in astrocytes of GFAP-CB1-RS. Only residual CB1 immu-
noparticles are in astrocytic processes of STOP-CB1 (1.76%61.29%), GFAP-CB1-KO (1.96%61.28%), CB1-KO (1.02%6 .72%) and
GFAPhrGFP-CB1-KO (1.62%6 .94%). (d) Proportion of immunogold particles on synaptic terminals versus total CB1 receptor expression on
plasmalemma: 65.52%62.44% (CB1-WT), 75.13%64.06% (GFAP-CB1-KO), and 56.32%62.73% (GFAPhrGFP-CB1-WT). Residual CB1
receptor immunoparticles are in astrocytes of GFAP-CB1-RS (2.02%61.17%), STOP-CB1 (1.47%6 .84%), CB1-KO (1.52%6 .87%) and
GFAPhrGFP-CB1-KO (2.08%61.19%). Data are expressed as mean6 SEM of three different animals. Data were analyzed by means of
Kruskal-Wallis Test and the Dunn’s Multiple Comparison Post-hoc test. ***p< .001; **p< .01; *p< .05. As: astrocytic processes; ter: termi-
nal; part: immunoparticles
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immunostaining, a cytoskeletal protein assembled in intermediate fila-
ment packets (Hol & Pekny, 2015), is mostly restricted to the main
branches of the astrocyte. However, hrGFP is a diffusible protein
extending into the delicate astrocytic processes that normally lack
GFAP (Nolte et al., 2001), accomplishing better detection of the astro-
cyte processes. Finally, maybe there epigenetic mechanisms leading to
the difference between GFAPhrGFP-CB1-WT and GFAP-CB1-RS, as in
rescue mice re-expression was induced in the adult.
The rescue of CB1 receptors in mice expressing the gene exclu-
sively in dorsal telencephalic glutamatergic neurons (Glu-CB1-RS) or in
forebrain GABAergic neurons (GABA-CB1-RS) (de Salas-Quiroga et al.,
2015; Lange et al., 2017; Remmers et al., 2017; Ruehle et al., 2013;
Soria-Gomez et al., 2014) has provided interesting insights into the suf-
ficiency of the CB1 receptor in these cells for specific brain functions
and behaviors. Therefore, restoration of CB1 receptor expression in
astrocytes and astroglial mitochondria could represent a new approach
to assess the function of the tripartite synapse. CB1 receptors in astro-
cytes play a key role in the two-way communication between neurons
and astrocytes through rising calcium in astrocytes that modulates syn-
aptic transmission and plasticity (Araque, Castillo, Manzoni, & Tonini,
2017; Gomez-Gonzalo et al., 2015; Martin-Fernandez et al., 2017;
Navarrete & Araque, 2008, 2010; Navarrete et al., 2013; Navarrete,
Diez, & Araque, 2014). Astroglial CB1 receptor activation regulates
astrocytic D-aspartate uptake (Shivachar, 2007) and might contribute
to the brains energy supply through the control of leptin receptors
expression in astrocytes (Bosier et al., 2013). Furthermore, CB1 recep-
tor expression increases in astrocytes of the sclerotic hippocampus
(Meng et al., 2014) and blockade of the astroglial CB1 receptors modu-
lates the intracellular calcium signaling dampening epileptiform activity
(Coiret et al., 2012). In addition, a strong decrease in CB1 receptors in
FIGURE 6 Statistical assessment of the CB1 receptor distribution on astrocytes in the dentate molecular layer of the mutant mice. (a).
Similar percentages of CB1 receptor immunopositive astrocytic processes in CB1-WT (44.67%63.85%) and GFAP-CB1-RS (39.84%63.50%)
are found. Statistical differences are obtained in GFAPhrGFP-CB1-WT (59.99%63.37%). Just residual particles are in: STOP-CB1 (1.33%6
.64%), GFAP-CB1-KO (1.59%6 .66%), CB1-KO (1.19%6 .71%) and GFAPhrGFP-CB1-KO (.47%6 .36%). The number of astrocytic processes
studied is in parentheses on the top of each column. (b) Analysis of CB1 receptor density (particles/mm) on astrocytic processes shows no
statistical differences between CB1-WT (.1126 .011) and GFAP-CB1-RS (.1386 .016); however, the density on GFAPhrGFP-CB1-WT (.3346
.033) is statistically higher. Only residual background is counted in STOP-CB1 (.0066 .003), GFAP-CB1-KO (.0066 .003), CB1-KO (.0046
.002) and GFAPhrGFP-CB1-KO (.0026 .002). (c) Proportion of CB1 receptor immunoparticles on astrocytic membranes versus total CB1
receptor expression on plasmalemma: 5.35%61.00% (CB1-WT), 95.61%61.56% (GFAP-CB1-RS). Almost null non-specific immunoparticles
are found in STOP-CB1 (1.65%6 .66%), GFAP-CB1-KO (1.45%61.45%), CB1-KO (1.43%61.43%) and GFAPhrGFP-CB1-KO (1.37%61.37%).
(d) Proportion of immunogold particles localized on synaptic terminals versus total CB1 receptor expression on plasmalemma: 64.27%6
2.88% (CB1-WT), 76.17%64.70% (GFAP-CB1-KO), 57.17%62.19% (GFAPhrGFP-CB1-WT). Only background levels are in synaptic terminals
of GFAP-CB1-RS (2.19%61.10%), STOP-CB1 (2.36%6 .85%), CB1-KO (2.14%61.22%) and GFAPhrGFP-CB1-KO (2.06%61.52%). Data are
expressed as mean6 SEM of three different animals. Data were analyzed by means of Kruskal-Wallis test and the Dunn’s multiple
comparison post-hoc test. ***p< .001; **p< .01; *p< .05. As: astrocytic processes; ter: terminal; part: immunoparticles
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adult mouse CA1 astrocytes has been recently observed after adoles-
cent drinking-in-the-dark ethanol intake patterns (Bonilla-Del Río et al.,
2017). Taken together, the subcellular compartmentalization of the
CB1 receptor in astrocytes suggests the existence of specific and pre-
cise distribution of the receptor that seems to be crucial for the func-
tional role of the CB1 receptor at the tripartite synapse (Araque et al.,
2014; Araque, Castillo, Manzoni, & Tonini, 2017; Belluomo et al., 2015;
Han et al., 2012; Metna-Laurent & Marsicano, 2015; Navarrete & Ara-
que, 2008, 2010; Oliveira da Cruz et al., 2015; Perez-Alvarez et al.,
2014).
4.1 | CB1 receptors in astroglial mitochondria and
potential functional implications
We estimated that 10%–15% of the total CB1 receptor labeling in the
hippocampus is localized at mitochondrial membranes (Benard et al.,
2012; Bonilla-Del Río et al., 2017; Hebert-Chatelain et al., 2016), and
this percentage is increased in muscle and heart (Mendizabal-Zubiaga
et al., 2016). Yet, about 22% of the mitochondrial sections in axon ter-
minals and somatodendritic domains contain CB1 receptors (Hebert-
Chatelain et al., 2014a,b). In the present study, 11%–13% of the astro-
cytic mitochondrial sections were CB1 receptor immunopositive,
FIGURE 7 Proportion of CB1 receptor immunopositive astrocytic mitochondria in the CA1 and dentate molecular layer of wild-type and
mutant mice. (a) Values of the CB1 receptor immunopositive astrocytic mitochondria in GFAP-CB1-RS (12.39%61.81%) and GFAPhrGFP-
CB1-WT (13.12%62.53%) are closely similar to CB1-WT (11.12%61.79%) in the CA1 stratum radiatum. The background in astroglial mito-
chondria is: STOP-CB1 (4.66%61.55%), GFAP-CB1-KO (3.97%61.71%), CB1-KO (2.97%61.15%) and GFAPhrGFP-CB1-KO (.95%6 .95%).
The number of total mitochondria examined is in parentheses on the top of each column. (b) In the dentate molecular layer, the values of
CB1 receptor immunopositive astrocytic mitochondria in GFAP-CB1-RS (11.48%61.76%) and GFAPhrGFP-CB1-WT (13.74%63.20%) are
comparable to the CB1-WT (11.56%62.33%). Background in astroglial mitochondria is: STOP-CB1 (5.38%61.22%), GFAP-CB1-KO (3.05%6
1.04%), CB1-KO (2.49%6 .80%), GFAPhrGFP-CB1-KO (1.98%6 .91%). The number of total mitochondria examined is in parentheses on the
top of each column. Data are expressed as mean6 SEM of three different animals. Data were analyzed by means of Kruskal-Wallis test and
the Dunn’s multiple comparison post-hoc test. ***p< .001; **p< .01; *p< .05. As: astrocytic processes; mito: mitochondria
FIGURE 8 Distance from the mitochondrial CB1 receptor particles in astrocytes to the synapses in the hippocampus. The distance
between the CB1 receptor particles on mitocondrial membranes in astrocytic processes and the midpoint of the nearest synapse surrounded
by them was assessed in the CA1 (a) and dentate molecular layer (b) of CB1-WT, GFAP-CB1-RS and GFAPhrGFP-CB1-WT (see Table 1 for
values)
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indicating that mtCB1 receptors in astrocytes might play important
functional roles. Indeed, their activation may impact functions in which
astroglial CB1 receptors are involved, such as metabolic activity, neuro-
protection, inflammatory responses, astrocyte development and sur-
vival, synaptic transmission, plasticity or memory formation (Aguado
et al., 2006; Araque et al., 2014; Araque, Castillo, Manzoni, & Tonini,
2017; Bosier et al., 2013; Han et al., 2012; Metna-Laurent &
Marsicano, 2015; Navarrete & Araque, 2008, 2010; Stella, 2010).
CB1 receptors in astrocytes, but not in glutamatergic or GABAergic
synaptic terminals, are responsible for long-term depression of synaptic
efficacy at hippocampal CA3-CA1 synapses in vivo and the subsequent
spatial working memory impairments induced by cannabinoid adminis-
tration (Han et al., 2012). Outside of the hippocampus, endocannabi-
noids acting on astroglial CB1 receptors in the central amygdala can
regulate fear responses by selectively reducing excitatory transmission
through synaptic A1 adenosine receptors and increasing inhibitory
transmission by synaptic A2A receptors (Martin-Fernandez et al.,
2017). Over the last decade, extensive study of mitochondrial CB1
receptors has begun to establish their function and how their activity
can modulate behaviors. The activation of mitochondrial CB1 receptors
leads to a remarkable decrease in mitochondrial respiration in brain
mitochondria (Benard et al., 2012; Hebert-Chatelain et al., 2014a,b,
2016) and the cannabinoid shutdown of hippocampal mitochondrial
activity produces a decrease in cellular and mitochondrial ATP, reduces
mitochondrial mobility, CA3-CA1 excitatory synaptic transmission and
abolishes discrimination of novel object recognition (Hebert-Chatelain
et al., 2016). The potential involvement of astroglial mtCB1 receptors in
these effects is currently not known and future studies will address this
interesting issue.
One open question is how the (endo)cannabinoids have access to
the mtCB1 receptors in astrocytes. With this aim in mind we took
advantage of the enhanced detection of the astrocytic CB1 receptors
in the CA1 stratum radiatum and dentate molecular layer of
GFAPhrGFP-CB1-WT mice. Then, the gap between the mitochondrial
CB1 receptor particles and the nearest synapse was measured to
understand the anatomical relationship of the receptor in the context
of the functional tripartite synapse (Araque et al., 2014; Navarrete &
Araque, 2008, 2010; Navarrete et al., 2013; Navarrete, Diez, & Araque,
2014). The most frequent distance of 400–800 nm spanning up to
1,200 nm suggests that the endocannabinoids generated on demand in
the postsynaptic neurons would need to travel a significant distance in
order to reach the CB1 receptors localized on the astroglial mitochon-
dria. However, astrocytes are able to produce endocannabinoids (Stella,
2010), contain the main enzymes for their synthesis and degradation
(Suarez et al., 2010; Uchigashima et al., 2011) and brain mitochondria
also contain these lipid signaling molecules (Benard et al., 2012). Con-
sidering that endocannabinoids can signal in autocrine, paracrine or
both manners (Metna-Laurent & Marsicano, 2015), it is possible that
astrocytes or even astroglial mitochondria might produce “their own”
endocannabinoids to specifically activate mtCB1 receptors.
Altogether, activation of intracellular CB1 receptors localized at
mitochondria impacts cognition through the modulation of mitochon-
drial energy metabolism (Hebert-Chatelain et al., 2016). Whether mito-
chondrial CB1 receptors also regulate the organelles energy production
in astrocytes and participate in high brain functions will be elucidated
in future studies.
4.2 | Conditional CB1 receptor mutants
Loss of function in mutant mice lacking CB1 receptors in specific cell
types allowed insights into their anatomical localization and a deeper
understanding of their necessary role for several brain functions
(Benard et al., 2012; Han et al., 2012; Koch et al., 2015; Marsicano
et al., 2003; Martín-García et al., 2016; Monory et al., 2006; Monory,
Polack, Remus, Lutz, & Korte, 2015; Soria-Gomez et al., 2014). Condi-
tional mutant mice lacking CB1 receptors in astrocytes exhibit neither
in vivo hippocampal long-term depression nor the impairment of spatial
working memory typically observed following acute cannabinoid treat-
ment (Han et al., 2012). The GFAP-CB1-RS mouse expressing CB1
receptors exclusively in astrocytes described here, together with the
Glu-CB1-RS rescue mouse expressing the receptor only in dorsal telen-
cephalic glutamatergic neurons (de Salas-Quiroga et al., 2015; Lange
et al., 2017; Ruehle et al., 2013; Soria-Gomez et al., 2014) and the
GABA-CB1-RS rescue mouse expressing the CB1 receptor only in
GABAergic neurons (de Salas-Quiroga et al., 2015; Lange et al., 2017)
that were recently characterized anatomically (Gutierrez-Rodríguez
TABLE 1 Proportion of synapses visualized in 400-nm-bit ranges from the CB1 receptor labeling in astroglial mitochondria
CA1 CB1-WT (1,790 lm
2) GFAP-CB1-RS (2,100 lm
2) GFAPhrGFP-CB1-WT (784 lm
2)
<400 nm 10.55%64.01% 2.67%62.67% 7.41%6 3.70%
400–800 nm 38.54%68.32% 49.28%6 2.87% 51.85%63.70%
800–1,200 nm 29.51%66.85% 37.26%6 2.02% 29.63%67.41%
>1,200 nm 21.40%65.56% 10.79%6 2.94% 14.81%67.41%
MDG CB1-WT (784 lm
2) GFAP-CB1-RS (1,708 lm
2) GFAPhrGFP-CB1-WT (1,512 lm
2)
<400 nm 11.11%66.42% 2.82%61.48% 1.52%6 1.52%
400–800 nm 50.0%63.21% 41.57%6 4.81% 57.37%6 6.26%
800–1,200 nm 23.15%6 .93% 43.79%6 3.13% 35.86%62.53%
>1,200 nm 18.52%63.70% 11.82%6 3.51% 5.25%6 2.72%
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et al., 2017; Remmers et al., 2017), suggest that the regulation of the
CB1 receptor expression in astrocytes, glutamatergic neurons and
GABAergic neurons may be independent of each others. The present
demonstration that the GFAP-CB1-RS in the hippocampus maintains
the normal CB1 receptor expression and distribution in astrocytes
make these mutants ideal suited for the study of the astroglial CB1
receptor function, as shown for Glu-CB1-RS (de Salas-Quiroga et al.,
2015; Gutierrez-Rodríguez et al., 2017; Lange et al., 2017; Ruehle
et al., 2013; Soria-Gomez et al., 2014) and GABA-CB1-RS mice (de
Salas-Quiroga et al., 2015; Gutierrez-Rodríguez et al., 2017; Lange
et al., 2017; Remmers et al., 2017). In fact, these rescue strategies have
the advantage of the restoration and visualization of existing CB1
receptor levels in locations with sparse CB1 receptors (as the astrocytes
and astroglial mitochondria), allowing a more comprehensive functional
characterization of the (endo)cannabinoid system based on the precise
cellular and subcellular localization of the CB1 receptor. At the same
time, these strategies improve the fundamental knowledge for the
development of innovative therapeutics in the struggle against brain
diseases.
Altogether, our observations confirm the high specificity of the
genetic CB1 receptor rescue approach carried out in the astrocytes and
that these mutant mice are emerging as excellent models for studying
the contribution of the CB1 receptors in astrocytes and astroglial mito-
chondria that, although scarce in expression as compared with their
neuronal counterparts, are a constant feature and likely play a key role
in brain function and dysfunction.
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